Schneider E, Yamazaki H, Sinha B K, Cowan K H
Medicine Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Br J Cancer. 1995 Apr;71(4):738-43. doi: 10.1038/bjc.1995.144.
Preincubation of etoposide-resistant human MCF7 breast cancer cells (MCF7/VP) with buthionine sulphoximine (BSO) resulted in their sensitisation to etoposide and vincristine. Chemosensitisation was accompanied by elevated intracellular drug levels. In contrast, simultaneous exposure to BSO did not result in increased drug accumulation. Similar, but quantitatively smaller, effects were also observed when sensitive wild-type MCF7/WT cells were treated with BSO. In agreement with its effect on drug accumulation, BSO pretreatment also increased VP-16-stimulated cleavable complex formation between DNA topoisomerase II and cellular DNA. BSO treatment also led to a significant increase in acid-precipitable VP-16 levels in MCF7/VP, but not MCF7/WT cells. In contrast, no clear effects of BSO on drug efflux were observed and drug retention was only minimally increased after BSO treatment of both MCF7/WT and MCF7/VP cells and no difference between the two cell lines was detected. Thus, chemosensitisation by BSO appeared to be mediated through increased intracellular drug concentrations and/or protein binding.
用丁硫氨酸亚砜胺(BSO)对依托泊苷耐药的人MCF7乳腺癌细胞(MCF7/VP)进行预孵育,使其对依托泊苷和长春新碱敏感。化学增敏伴随着细胞内药物水平升高。相比之下,同时暴露于BSO并未导致药物积累增加。当用BSO处理敏感的野生型MCF7/WT细胞时,也观察到了类似但数量上较小的效应。与其对药物积累的影响一致,BSO预处理还增加了VP-16刺激的DNA拓扑异构酶II与细胞DNA之间可切割复合物的形成。BSO处理还导致MCF7/VP细胞中酸沉淀的VP-16水平显著增加,但MCF7/WT细胞中未增加。相比之下,未观察到BSO对药物外排有明显影响,并且在对MCF7/WT和MCF7/VP细胞进行BSO处理后,药物保留仅略有增加,且未检测到两种细胞系之间的差异。因此,BSO的化学增敏作用似乎是通过增加细胞内药物浓度和/或蛋白质结合来介导的。